novartis ag switzerland clears tasigna potential gleevec successor drug company novartis ag said switzerland has granted the first approval world wide for its tasigna cancer drug a potential follow up to gleevec the swiss company said tasigna is a new targeted cancer drug for patients with a form of life threatening blood cancer chronic myeloid leukemia who are resistant or intolerant to treatment with gleevec novartis expects tasigna to eventually replace gleevec known as glivec outside the u s and which generated sales of &# billion last year 
